Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-arm study of apremilast in Japanese children and adolescents with moderate to severe plaque psoriasis
jRCT2031220486Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of apremilast in plaque psoriasis, sponsored by Amgen. Primary endpoint: Achievement of sPGA response. Started Jan 2023; status: active, not recruiting.
02
Drugs
apremilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCT2031220486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220486.